Position in GRFS
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$376
New position
Shares Held
47
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SALEM INVESTMENT COUNSELORS INC holds $225,886,114 across 15 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
78,924 | $94,663,821 | |
| 2 | JNJ |
Johnson & Johnson
|
176,284 | $44,770,847 | |
| 3 | ABBV |
AbbVie Inc.
|
132,322 | $33,297,508 | |
| 4 | MRK |
Merck & Co., Inc.
|
176,330 | $22,658,405 | |
| 5 | AMGN |
Amgen Inc
|
32,937 | $11,927,146 | |
| 6 | NVS |
Novartis AG
|
71,102 | $11,143,105 | |
| 7 | NVO |
Novo Nordisk A S
|
61,839 | $2,964,561 | |
| 8 | PFE |
Pfizer Inc
|
106,893 | $2,573,983 |
All Filings in GRFS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $376 | 47 | Shares | Sole | 2026-04-29 | |
| No filing history on record for this holder in this stock. | ||||||